Trinity Biotech (TRIB) Asset Writedowns and Impairment (2022 - 2023)
Trinity Biotech (TRIB) posted quarterly Asset Writedowns and Impairment of $290000.0 for Q4 2023, up 113.98% year-on-year from $135529.3 in Q4 2022, and up 113.98% on a QoQ basis from -$2.1 million in Q4 2022.
Trinity Biotech (TRIB) Asset Writedowns and Impairment (2022 - 2023) Analysis & Trends
Trinity Biotech (TRIB) has reported Asset Writedowns and Impairment for 2 consecutive years, with $290000.0 the latest figure, recorded in Q4 2023.
- Quarterly Asset Writedowns and Impairment rose 113.98% year-over-year to $290000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $503000.0 (changed N/A YoY) and the FY2025 annual result came in at $2.2 million, up 54.62% from the prior year.
- Asset Writedowns and Impairment climbed to $290000.0 in Q4 2023 per TRIB's latest filing, from -$2.1 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for TRIB reached as high as $2.3 million in Q3 2022 and fell as low as -$2.1 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Trinity Biotech | 93,750.00 | -5.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 290,000.00 |
| Dec 31, 2023 | 290,000.00 |
| Dec 31, 2022 | -2.08 Mn |
| Dec 31, 2022 | -2.08 Mn |
| Sep 30, 2022 | 2.29 Mn |
| Sep 30, 2022 | 2.29 Mn |